- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06468033
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
June 14, 2024 updated by: PharmaEssentia
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus
This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk.
Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ting-Fang Wang
- Phone Number: +886-2-26557688
- Email: tingfang_wang@pharmaessentia.com
Study Contact Backup
- Name: Aypiin Shen
- Phone Number: +886-2-26557688 Ext. 7896
- Email: aypiin_shen@pharmaessentia.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female patients aged ≥18 years at the time of signing the informed consent form;
- Patients with pre-fibrotic/early PMF (Pre-PMF) or overt primary myelofibrosis at low to intermediate-1 risk according to DIPSS plus, diagnosed according to WHO 2016 or 2022 classification;
- With good liver function at screening, which is defined as total bilirubin ≤1.5 × upper limit of normal (ULN), international normalized ratio (INR) ≤1.5 × ULN, albumin >3.5 g/dL, alanine aminotransferase (ALT) ≤2.0 × ULN, and aspartate aminotransferase (AST) ≤2.0 × ULN;
- Hgb ≥10.0 g/dL at screening;
- Neutrophil count ≥1.0 × 10^9/L at screening;
- Creatinine clearance rate ≥30 mL/min at screening (according to the Cockcroft-Gault formula);
- Females of childbearing potential, as well as all women <2 years after the onset of menopause, must agree to use an acceptable form of birth control until 60 days following the last dose of the study drug, and females must agree to not breastfeed during the study;
- Written informed consent obtained from the subject and ability for the subject to comply with the requirements of the study.
Exclusion Criteria:
- Any known contraindications to interferon α or hypersensitivity to interferon α;
- Patients with prior interferon therapy having poor tolerability or lack of efficacy to the previous interferon therapy per investigator's judgement;
- Patients with an ongoing cytoreduction (e.g., HU or IFN-α) at the time of screening if, in the Investigator's opinion, randomizing them into the placebo arm will lead to immediate rebound increase of peripheral blood counts and thus may jeopardize their health status;
- With severe or serious diseases that, in the Investigator's opinion, may affect the patient's participation in this study;
- History of major organ transplantation;
- Pregnant or breastfeeding women;
- Patients with any other diseases that will affect the study results or may weaken the compliance to protocol per the Investigator's judgment;
- Use any investigational drug <4 weeks prior to the first dose of study drug, or not recovered from effects of prior administration of any investigational drug.
- Eligible for JAK inhibitor therapy at screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study group
Ropeginterferon alfa-2b is administrated subcutaneously (SC) every two weeks (± 3 days) until 56 weeks.
|
Pre-filled Syringe. Dosage: up to 500mcg
Other Names:
|
Placebo Comparator: Control group
Placebo is administrated subcutaneously (SC) every two weeks (± 3 days) until 56 weeks.
|
Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically relevant Complete Hematologic Response (CrCHR): Platelet count, and
Time Frame: 56 weeks
|
≤400 × 10^9/L
|
56 weeks
|
CrCHR: White Blood Cells (WBC) count, and
Time Frame: 56 weeks
|
<10 × 10^9/L
|
56 weeks
|
CrCHR: Peripheral blood: Hemoglobin (Hgb), and
Time Frame: 56 weeks
|
>10.0 g/dL
|
56 weeks
|
CrCHR: Absence of thrombotic events, and
Time Frame: 56 weeks
|
Absence of major thrombotic events during the observation time frame
|
56 weeks
|
CrCHR: No progression to AML, or
Time Frame: 56 weeks
|
No progression to secondary acute myeloid leukemia (AML)
|
56 weeks
|
Symptom endpoint
Time Frame: 56 weeks
|
No progression on clinical symptoms based on the MFSAF Total Symptom Score (TSS) v4.0
|
56 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Toshiaki Sato, MD/PhD, PharmaEssentia JP
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2024
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
August 1, 2027
Study Registration Dates
First Submitted
June 10, 2024
First Submitted That Met QC Criteria
June 14, 2024
First Posted (Estimated)
June 21, 2024
Study Record Updates
Last Update Posted (Estimated)
June 21, 2024
Last Update Submitted That Met QC Criteria
June 14, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A23-302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Myelofibrosis
-
The University of Hong KongRecruitingMyelofibrosis | Primary Myelofibrosis, Prefibrotic StageHong Kong
-
Assaf-Harofeh Medical CenterUnknownMyelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ETIsrael
-
Centre Hospitalier Annecy GenevoisCompleted
-
University of Kansas Medical CenterNot yet recruiting
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Puerto Rico, Russian Federation, Serbia, South... and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Spain, Sweden, Turkey, Korea, Republic of
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
-
AbbVieTerminatedMyelofibrosis (MF)United States, Korea, Republic of, South Africa
-
National Taiwan University HospitalRecruitingPre-fibrotic MyelofibrosisTaiwan
-
Telios Pharma, Inc.RecruitingPrimary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET MyelofibrosisSpain, United States, France, Poland, Italy, Germany
Clinical Trials on Ropeginterferon alfa-2b
-
PharmaEssentiaRecruitingPolycythemia VeraUnited States, Canada
-
The University of Hong KongRecruitingMyelofibrosis | Primary Myelofibrosis, Prefibrotic StageHong Kong
-
PharmaEssentia Japan K.K.PharmaEssentiaCompleted
-
PharmaEssentiaNot yet recruitingPolycythemia Vera | Myeloproliferative Neoplasm
-
National Taiwan University HospitalRecruitingPre-fibrotic MyelofibrosisTaiwan
-
PharmaEssentiaRecruitingEssential ThrombocythemiaUnited States, Canada
-
PharmaEssentiaActive, not recruiting
-
National Taiwan University HospitalPharmaEssentiaRecruitingChronic Hepatitis B Virus InfectionTaiwan
-
National Taiwan University HospitalNot yet recruiting
-
PharmaEssentia Japan K.K.RecruitingPolycythemia Vera (PV)Japan